API5 Confers Tumoral Immune Escape through FGF2-Dependent Cell Survival Pathway
- Authors
- Noh, Kyung Hee; Kim, Seok-Ho; Kim, Jin Hee; Song, Kwon-Ho; Lee, Young-Ho; Kang, Tae Heung; Han, Hee Dong; Sood, Anil K.; Ng, Joanne; Kim, Kwanghee; Sonn, Chung Hee; Kumar, Vinay; Yee, Cassian; Lee, Kyung-Mi; Kim, Tae Woo
- Issue Date
- 1-7월-2014
- Publisher
- AMER ASSOC CANCER RESEARCH
- Citation
- CANCER RESEARCH, v.74, no.13, pp.3556 - 3566
- Indexed
- SCIE
SCOPUS
- Journal Title
- CANCER RESEARCH
- Volume
- 74
- Number
- 13
- Start Page
- 3556
- End Page
- 3566
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/97988
- DOI
- 10.1158/0008-5472.CAN-13-3225
- ISSN
- 0008-5472
- Abstract
- Identifying immune escape mechanisms used by tumors may define strategies to sensitize them to immunotherapies to which they are otherwise resistant. In this study, we show that the antiapoptotic gene API5 acts as an immune escape gene in tumors by rendering them resistant to apoptosis triggered by tumor antigen-specific T cells. Its RNAi-mediated silencing in tumor cells expressing high levels of API5 restored antigen-specific immune sensitivity. Conversely, introducing API5 into API5(low) cells conferred immune resistance. Mechanistic investigations revealed that API5 mediated resistance by upregulating FGF2 signaling through a FGFR1/PKC delta/ERK effector pathway that triggered degradation of the proapoptotic molecule BIM. Blockade of FGF2, PKC delta, or ERK phenocopied the effect of API5 silencing in tumor cells expressing high levels of API5 to either murine or human antigen-specific T cells. Our results identify a novel mechanism of immune escape that can be inhibited to potentiate the efficacy of targeted active immunotherapies. (C) 2014 AACR.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.